Literature DB >> 2981427

Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

J Sodroski, C Rosen, F Wong-Staal, S Z Salahuddin, M Popovic, S Arya, R C Gallo, W A Haseltine.   

Abstract

Human T-cell leukemia virus type III (HTLV-III) was recently identified as the probable etiologic agent of the acquired immune deficiency syndrome (AIDS). Here it is shown that, in human T-cell lines infected with HTLV-III, gene expression directed by the long terminal repeat sequence of this virus is stimulated by more than two orders of magnitude compared to matched uninfected cells. The rate of transcription of the HTLV-III long terminal repeat is more than 1000 times that of the SV40 early promoter in one infected cell line. Thus, HTLV-III, like HTLV-I, HTLV-II, and the bovine leukemia virus, is characterized by trans-activation of transcription in infected cells. The efficiency of trans-activation in the case of HTLV-III may account, at least in part, for the virulent nature of HTLV-III infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981427     DOI: 10.1126/science.2981427

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  178 in total

1.  Molecular dynamics simulations on HIV-1 Tat.

Authors:  Sergio Pantano; Mudit Tyagi; Mauro Giacca; Paolo Carloni
Journal:  Eur Biophys J       Date:  2003-11-08       Impact factor: 1.733

2.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 3.  Transcriptional and posttranscriptional regulation of HIV-1 gene expression.

Authors:  Jonathan Karn; C Martin Stoltzfus
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

4.  Structural analysis of wild-type and mutant human immunodeficiency virus type 1 Tat proteins.

Authors:  A P Rice; F Carlotti
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure.

Authors:  S M Holland; N Ahmad; R K Maitra; P Wingfield; S Venkatesan
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types.

Authors:  E K Ross; A J Buckler-White; A B Rabson; G Englund; M A Martin
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

7.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

Review 8.  Molecular mechanisms of HIV latency.

Authors:  Daniele C Cary; Koh Fujinaga; B Matija Peterlin
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 9.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

10.  Localization of sequences responsible for trans-activation of the equine infectious anemia virus long terminal repeat.

Authors:  L Sherman; A Gazit; A Yaniv; T Kawakami; J E Dahlberg; S R Tronick
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.